125 related articles for article (PubMed ID: 12637464)
1. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
Buzdar A; O'Shaughnessy JA; Booser DJ; Pippen JE; Jones SE; Munster PN; Peterson P; Melemed AS; Winer E; Hudis C
J Clin Oncol; 2003 Mar; 21(6):1007-14. PubMed ID: 12637464
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
Baselga J; Llombart-Cussac A; Bellet M; Guillem-Porta V; Enas N; Krejcy K; Carrasco E; Kayitalire L; Kuta M; Lluch A; Vodvarka P; Kerbrat P; Namer M; Petruzelka L
Ann Oncol; 2003 Sep; 14(9):1383-90. PubMed ID: 12954577
[TBL] [Abstract][Full Text] [Related]
3. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.
Deshmane V; Krishnamurthy S; Melemed AS; Peterson P; Buzdar AU
J Clin Oncol; 2007 Nov; 25(31):4967-73. PubMed ID: 17971595
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD
J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463
[TBL] [Abstract][Full Text] [Related]
5. Arzoxifene as therapy for endometrial cancer.
Burke TW; Walker CL
Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S40-6. PubMed ID: 12928005
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Münster PN; Buzdar A; Dhingra K; Enas N; Ni L; Major M; Melemed A; Seidman A; Booser D; Theriault R; Norton L; Hudis C
J Clin Oncol; 2001 Apr; 19(7):2002-9. PubMed ID: 11283133
[TBL] [Abstract][Full Text] [Related]
7. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Garnett S; Lindemann JP; Sapunar F; Martin M
J Clin Oncol; 2010 Oct; 28(30):4594-600. PubMed ID: 20855825
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Detre S; Riddler S; Salter J; A'Hern R; Dowsett M; Johnston SR
Cancer Res; 2003 Oct; 63(19):6516-22. PubMed ID: 14559845
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
10. A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.
Johnston SR; Gumbrell LA; Evans TR; Coleman RE; Smith IE; Twelves CJ; Soukop M; Rea DW; Earl HM; Howell A; Jones A; Canney P; Powles TJ; Haynes BP; Nutley B; Grimshaw R; Jarman M; Halbert GW; Brampton M; Haviland J; Dowsett M; Coombes RC;
Cancer Chemother Pharmacol; 2004 Apr; 53(4):341-8. PubMed ID: 14722733
[TBL] [Abstract][Full Text] [Related]
11. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
[TBL] [Abstract][Full Text] [Related]
12. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
Ohno S; Rai Y; Iwata H; Yamamoto N; Yoshida M; Iwase H; Masuda N; Nakamura S; Taniguchi H; Kamigaki S; Noguchi S
Ann Oncol; 2010 Dec; 21(12):2342-2347. PubMed ID: 20494961
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
14. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
[TBL] [Abstract][Full Text] [Related]
15. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy.
Licun W; Tannock IF
Clin Cancer Res; 2003 Oct; 9(12):4614-8. PubMed ID: 14555537
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Mocellin S; Pilati P; Briarava M; Nitti D
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582062
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
Fabian CJ; Kimler BF; Anderson J; Tawfik OW; Mayo MS; Burak WE; O'Shaughnessy JA; Albain KS; Hyams DM; Budd GT; Ganz PA; Sauter ER; Beenken SW; Grizzle WE; Fruehauf JP; Arneson DW; Bacus JW; Lagios MD; Johnson KA; Browne D
Clin Cancer Res; 2004 Aug; 10(16):5403-17. PubMed ID: 15328178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
